Search Results

Shockwave Medical, Inc. today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”).

Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy to treat severely calcified cardiovascular disease, announced the completion of its previously announced acquisition of Neovasc Inc..

Neovasc, Inc. announced the German Institute for the Hospital Remuneration System has awarded the Neovasc Reducer™, a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) announced today that the Company has entered into a binding agreement (the “Arrangement Agreement”) with Shockwave Medical, Inc. (“Shockwave”), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the “Common Shares”) of the Company (the “Transaction”).

Neovasc Inc. is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the “Shares”) by Shockwave Medical, Inc.